Literature DB >> 34318855

Analysis of pancreatic extracellular matrix protein post-translational modifications via electrostatic repulsion-hydrophilic interaction chromatography coupled with mass spectrometry.

Dylan Nicholas Tabang1, Yusi Cui1, Daniel M Tremmel2, Megan Ford3, Zihui Li1, Sara Dutton Sackett2, Jon S Odorico2, Lingjun Li1,4.   

Abstract

The pancreas is a vital organ with digestive and endocrine roles, and diseases of the pancreas affect millions of people yearly. A better understanding of the pancreas proteome and its dynamic post-translational modifications (PTMs) is necessary to engineer higher fidelity tissue analogues for use in transplantation. The extracellular matrix (ECM) has major roles in binding and signaling essential to the viability of insulin-producing islets of Langerhans. To characterize PTMs in the pancreas, native and decellularized tissues from four donors were analyzed. N-Glycosylated and phosphorylated peptides were simultaneously enriched via electrostatic repulsion-hydrophilic interaction chromatography and analyzed with mass spectrometry, maximizing PTM information from one workflow. A modified surfactant and chaotropic agent assisted sequential extraction/on-pellet digestion was used to maximize solubility of the ECM. The analysis resulted in the confident identification of 3650 proteins, including 517 N-glycoproteins and 148 phosphoproteins. We identified 214 ECM proteins, of which 99 were N-glycosylated, 18 were phosphorylated, and 9 were found to have both modifications. Collagens, a major component of the ECM, were the most highly glycosylated of the ECM proteins and several were also heavily phosphorylated, raising the possibility of structural and thus functional changes resulting from these modifications. To our knowledge, this work represents the first characterization of PTMs in pancreatic ECM proteins. This work provides a basal profile of PTMs in the healthy human pancreatic ECM, laying the foundation for future investigations to determine disease-specific changes such as in diabetes and pancreatic cancer, and potentially helping to guide the development of tissue replacement constructs. Data are available via ProteomeXchange with identifier PXD025048.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34318855      PMCID: PMC8511275          DOI: 10.1039/d1mo00104c

Source DB:  PubMed          Journal:  Mol Omics        ISSN: 2515-4184


  82 in total

1.  Two-dimensional target decoy strategy for shotgun proteomics.

Authors:  Marshall W Bern; Yong J Kil
Journal:  J Proteome Res       Date:  2011-11-07       Impact factor: 4.466

Review 2.  Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction.

Authors:  Maria Francisca Coutinho; Maria João Prata; Sandra Alves
Journal:  Mol Genet Metab       Date:  2011-12-23       Impact factor: 4.797

3.  In Depth Quantification of Extracellular Matrix Proteins from Human Pancreas.

Authors:  Fengfei Ma; Daniel M Tremmel; Zihui Li; Christopher B Lietz; Sara Dutton Sackett; Jon S Odorico; Lingjun Li
Journal:  J Proteome Res       Date:  2019-07-01       Impact factor: 4.466

4.  Clinical significance of CA 19.9 and LINC01197 in pancreatic cancer.

Authors:  Y-H Jia; W-W Zheng; Z-H Ye
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-03       Impact factor: 3.507

5.  Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer.

Authors:  Kim C Honselmann; Pascal Finetti; David J Birnbaum; Christian S Monsalve; Ulrich F Wellner; Sebastian K S Begg; Akifumi Nakagawa; Thomas Hank; Annie Li; Mathew A Goldsworthy; Himanshu Sharma; François Bertucci; Daniel Birnbaum; Eric Tai; Matteo Ligorio; David T Ting; Oliver Schilling; Martin L Biniossek; Peter Bronsert; Cristina R Ferrone; Tobias Keck; Mari Mino-Kenudson; Keith D Lillemoe; Andrew L Warshaw; Carlos Fernández-Del Castillo; Andrew S Liss
Journal:  Mol Cancer Res       Date:  2020-09-01       Impact factor: 5.852

6.  Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer.

Authors:  Jian Zheng; Jonathan M Hernandez; Alexandre Doussot; Linda Bojmar; Constantinos P Zambirinis; Bruno Costa-Silva; Elke J A H van Beek; Milica T Mark; Henrik Molina; Gokce Askan; Olca Basturk; Mithat Gonen; T Peter Kingham; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; David Lyden; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2018-01-12       Impact factor: 3.647

7.  Optimal Dissociation Methods Differ for N- and O-Glycopeptides.

Authors:  Nicholas M Riley; Stacy A Malaker; Marc D Driessen; Carolyn R Bertozzi
Journal:  J Proteome Res       Date:  2020-06-28       Impact factor: 4.466

8.  Proteome-wide and matrisome-specific alterations during human pancreas development and maturation.

Authors:  Zihui Li; Daniel M Tremmel; Fengfei Ma; Qinying Yu; Min Ma; Daniel G Delafield; Yatao Shi; Bin Wang; Samantha A Mitchell; Austin K Feeney; Vansh S Jain; Sara Dutton Sackett; Jon S Odorico; Lingjun Li
Journal:  Nat Commun       Date:  2021-02-15       Impact factor: 14.919

9.  Global Identification of Protein Post-translational Modifications in a Single-Pass Database Search.

Authors:  Michael R Shortreed; Craig D Wenger; Brian L Frey; Gloria M Sheynkman; Mark Scalf; Mark P Keller; Alan D Attie; Lloyd M Smith
Journal:  J Proteome Res       Date:  2015-09-29       Impact factor: 4.466

10.  A mass spectrometry-based assay using metabolic labeling to rapidly monitor chromatin accessibility of modified histone proteins.

Authors:  Simone Sidoli; Mariana Lopes; Peder J Lund; Naomi Goldman; Maria Fasolino; Mariel Coradin; Katarzyna Kulej; Natarajan V Bhanu; Golnaz Vahedi; Benjamin A Garcia
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

View more
  1 in total

1.  A Spin-Tip Enrichment Strategy for Simultaneous Analysis of N-Glycopeptides and Phosphopeptides from Human Pancreatic Tissues.

Authors:  Dylan Nicholas Tabang; Danqing Wang; Lingjun Li
Journal:  J Vis Exp       Date:  2022-05-04       Impact factor: 1.424

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.